

## Amendments to the Specification:

On page 1, please replace the paragraph beginning at line 18 with the following:

This work was supported in part by a grant from the National Institutes of Health (U54-NS48843). The United States Government ~~may have~~ has certain rights to the invention

On page 33, please replace the paragraph beginning at line 20 with the following:

SiRNA construct design and transfection: two custom siRNA duplexes were designed for RNAi against human MBNL1 using the Dharmacon siDESIGN program available on the world wide web at dharmacon.com, (~~www.dharmacon.com~~ (~~http://www.dharmacon.com/~~)) and were synthesized by Dharmacon. The sequences are as follows: THH31 mRNA target (AA-N19 format 5' → 3') AACAGACAGACUUGAGGUAUG (SEQ ID NO: 35), THH2 mRNA target (AA-N19 format 5' → 3') AACACGGAAUGUAAAUUUGCA (SEQ ID NO: 36), GFP siRNA duplex (Dharmacon, Lafayette, Colo. cat. no. D-001300-01-20). 300 000 HeLa cells were plated in 2 ml of antibiotic-free growth media (DMEM supplemented with 10% FBS) per well in a six-well plate. HeLa cells were chosen because they express MBNL1 (Miller J W, Urbinati C R, Teng-Umnay P, Stenberg M G, Byrne B J, Thornton C A, Swanson M S (2000), EMBO J 19: 4439-4448) and are amenable to siRNA-mediated depletion (Elbashir S M, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001), Nature 411: 494-498).